1. Home
  2. JQC vs AKBA Comparison

JQC vs AKBA Comparison

Compare JQC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

JQC

Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

HOLD

Current Price

$4.84

Market Cap

753.9M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.25

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JQC
AKBA
Founded
2003
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
753.9M
729.1M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
JQC
AKBA
Price
$4.84
$1.25
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$5.75
AVG Volume (30 Days)
842.3K
3.3M
Earning Date
01-01-0001
05-27-2026
Dividend Yield
11.13%
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.84
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.60
$1.14
52 Week High
$5.59
$4.08

Technical Indicators

Market Signals
Indicator
JQC
AKBA
Relative Strength Index (RSI) 31.79 43.18
Support Level N/A $1.14
Resistance Level $5.16 $1.57
Average True Range (ATR) 0.05 0.10
MACD -0.02 0.01
Stochastic Oscillator 15.71 22.83

Price Performance

Historical Comparison
JQC
AKBA

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: